About the CGBM

Logo des Centrums für geschlechtsspezifische Biologie und Medizin (CGBM)

The Centre for Gender-specific Biology and Medicine (CGBM) is a scientific institution at the Medical Faculty of Saarland University. It conducts research into the fundamental mechanisms of gender-specific diseases in order to generate new knowledge for their prevention, diagnosis and treatment. The CGBM works closely with internal university and university-affiliated institutions, other universities, research institutions and the healthcare industry in Germany and abroad.

 

 

Mission

The CGBM's mission is to improve the quality of life and health of people through research and understanding of gender-specific differences in biology and medicine. We strive to develop innovative and effective preventive, diagnostic and therapeutic approaches that are tailored to the individual needs of women and men. In doing so, we emphasise scientific excellence, interdisciplinary collaboration and social responsibility. Our aim is to optimise patient care, enrich medical education and contribute to shaping a fairer and healthier world.

Tasks

The CGBM is responsible for

  1. Tasks of life science and basic medical research as well as translational and clinical research, in particular
    • research into gender-specific signalling pathways of inter-organ communication
    • research into the molecular and cellular processes of diseases with a gender-specific distribution or manifestation,
    • research into the epidemiology of gender-specific diseases,
    • research into new diagnostic and therapeutic approaches that take gender differences into account;
  2. promoting the implementation of new teaching content on gender-specific diseases in medical and human and molecular biology degree programmes;
  3. the coordination and networking of existing activities and the initiation of further activities to investigate gender-specific diseases in basic research, clinical research and healthcare research;
  4. the establishment and maintenance of bilateral and multilateral regional, national and international networks with partners at university institutions, federal research institutions or other funding organisations and the healthcare industry;
  5. Participation in local, national and international networks with partners at university institutions, federal research institutions or other funding organisations and the healthcare industry;
  6. Participation in the improvement of patient care, in particular
    • in evaluating the current state of diagnosis, epidemiology and treatment of gender-specific diseases,
    • researching and implementing optimised care structures,
    • the provision of needs-based information for patients, relatives, the general public and decision-makers in business and politics.

Organisation